Cochrane · systematic review · CD012414
Penile rehabilitation for postprostatectomy erectile dysfunction
Philippou, YA, Jung, JH, Steggall, MJ, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
31
current version
GRADE rated
19
No studies
12
Included studies
NR
No studies 12 · 38.7%Ungraded 0 · 0%Very low 12 · 38.7%Low 3 · 9.7%Moderate 3 · 9.7%High 1 · 3.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Scheduled PDE5I compared to on demand placebo or no treatment for post‐prostatectomy erectile dysfunction (short‐term)
Population: post‐prostatectomy erectile dysfunction (short‐term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Self‐reported potency Scheduled PDE5I vs on demand placebo or no treatment | RR 1.13 [0.91, 1.41] | 4 studies · 628 participants | Very low Downgraded: risk of bias |
Erectile function Scheduled PDE5I vs on demand placebo or no treatment | RR 1.11 [0.8, 1.55] | 5 studies · 757 participants | Very low Downgraded: risk of bias |
Serious adverse events Scheduled PDE5I vs on demand placebo or no treatment | RR 0.32 [0.11, 0.94] | 3 studies · 443 participants | Low Downgraded: risk of bias |
Sexual quality of life ‐ not reported Scheduled PDE5I vs on demand placebo or no treatment | no estimate extracted | NR | No studies |
Treatment discontinuation Scheduled PDE5I vs on demand placebo or no treatment | RR 0.98 [0.72, 1.34] | 3 studies · 443 participants | Very low Downgraded: risk of bias |
International Index of Erectile Function Scheduled PDE5I vs on demand placebo or no treatment | no estimate extracted | 2 studies · 356 participants | Low Downgraded: risk of bias |
Scheduled PDE5I compared to on demand placebo or no treatment for post‐prostatectomy erectile dysfunction (long‐term)
Population: post‐prostatectomy erectile dysfunction (long‐term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Self‐reported potency ‐ not reported Scheduled PDE5I vs on demand placebo or no treatment | no estimate extracted | NR | No studies |
Erectile function ‐ not reported Scheduled PDE5I vs on demand placebo or no treatment | no estimate extracted | NR | No studies |
Serious adverse events ‐ not reported Scheduled PDE5I vs on demand placebo or no treatment | no estimate extracted | NR | No studies |
Sexual quality of life Scheduled PDE5I vs on demand placebo or no treatment | no estimate extracted | 1 study · 280 participants | Moderate Downgraded: imprecision |
Treatment discontinuation Scheduled PDE5I vs on demand placebo or no treatment | RR 1.12 [0.85, 1.48] | 1 study · 420 participants | Moderate Downgraded: imprecision |
International Index of Erectile Function ‐ not reported Scheduled PDE5I vs on demand placebo or no treatment | no estimate extracted | NR | No studies |
Scheduled PDE5I compared to on demand PDE5I for post‐prostatectomy erectile dysfunction (short‐term)
Population: post‐prostatectomy erectile dysfunction (short‐term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Self‐reported potency Scheduled PDE5I vs on demand PDE5I | RR 0.97 [0.62, 1.53] | 2 studies · 532 participants | Very low Downgraded: risk of bias |
Erectile function Scheduled PDE5I vs on demand PDE5I | RR 1 [0.65, 1.55] | 2 studies · 573 participants | Very low Downgraded: risk of bias |
Serious adverse events Scheduled PDE5I vs on demand PDE5I | RR 0.69 [0.12, 4.04] | 1 study · 282 participants | Very low Downgraded: risk of bias |
Sexual quality of life ‐ not reported Scheduled PDE5I vs on demand PDE5I | no estimate extracted | NR | No studies |
Treatment discontinuation Scheduled PDE5I vs on demand PDE5I | RR 1.35 [0.85, 2.12] | 1 study · 282 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
International Index of Erectile Function Scheduled PDE5I vs on demand PDE5I | no estimate extracted | 1 study · 281 participants | High |
Scheduled PDE5I compared to on demand PDE5I for post‐prostatectomy erectile dysfunction (long‐term)
Population: post‐prostatectomy erectile dysfunction (long‐term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Self‐reported potency Scheduled PDE5I vs on demand PDE5I | RR 1 [0.6, 1.67] | 1 study · 94 participants | Very low Downgraded: risk of bias |
Erectile function Scheduled PDE5I vs on demand PDE5I | RR 0.74 [0.48, 1.14] | 2 studies · 168 participants | Very low Downgraded: risk of bias |
Serious adverse events ‐ not reported Scheduled PDE5I vs on demand PDE5I | no estimate extracted | NR | No studies |
Sexual quality of life Scheduled PDE5I vs on demand PDE5I | no estimate extracted | 1 study · 281 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Treatment discontinuation Scheduled PDE5I vs on demand PDE5I | RR 1.09 [0.86, 1.38] | 3 studies · 612 participants | Very low Downgraded: risk of bias |
International Index of Erectile Function ‐ not reported Scheduled PDE5I vs on demand PDE5I | no estimate extracted | NR | No studies |
Scheduled PDE5I compared to scheduled intraurethral prostaglandin E1 for post‐prostatectomy erectile dysfunction (short term)
Population: post‐prostatectomy erectile dysfunction (short term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Self‐reported potency Scheduled PDE5I vs scheduled intraurethral prostaglandin E1 | RR 1.1 [0.79, 1.52] | 1 study · 156 participants | Very low Downgraded: risk of bias |
Erectile function Scheduled PDE5I vs scheduled intraurethral prostaglandin E1 | RR 1.64 [0.84, 3.2] | 1 study · 156 participants | Very low Downgraded: risk of bias |
Erectile function Scheduled PDE5I vs scheduled intraurethral prostaglandin E1 | RR 1.2 [0.79, 1.81] | 1 study · 156 participants | Very low Downgraded: risk of bias |
Serious adverse events ‐ not reported Scheduled PDE5I vs scheduled intraurethral prostaglandin E1 | no estimate extracted | NR | No studies |
Sexual quality of life ‐ not reported Scheduled PDE5I vs scheduled intraurethral prostaglandin E1 | no estimate extracted | NR | No studies |
Treatment discontinuation ‐ not reported Scheduled PDE5I vs scheduled intraurethral prostaglandin E1 | no estimate extracted | NR | No studies |
International Index of Erectile Function ‐ not reported Scheduled PDE5I vs scheduled intraurethral prostaglandin E1 | no estimate extracted | NR | No studies |